Shares of Moderna (NASDAQ: MRNA) fell 13.5% on Monday after health officials indicated that the omicron variant might lead to less severe forms of COVID-19 than feared. So what Omicron is a heavily mutated strain of the novel coronavirus. It appears to be more transmissible than the already worrisome delta variant.
Full Answer
Could Moderna stock help you retire a millionaire?
That's the advice from several financial experts across the country who said that investors shouldn't do anything rash with their 401(k) retirement accounts amid a turbulent 2022 stock ... If you are not maxing out your elective deferrals and can afford ...
Is it too late to buy Moderna stock?
With the stock down more than two-thirds from its peak in September, this could be a good buying opportunity for Moderna stock. The company has a number of different vaccine trials in the works on diseases, ranging from HIV to Zika to cancer. It's too ...
How much is Moderna really worth?
Today, after it developed and delivered one of the fastest-arriving and most effective shots against Covid-19, Moderna’s market value is approaching $100 billion. Some of the stock's 1,000% gain is undoubtedly warranted.
When will Moderna stock be a screaming buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Moderna (MRNA) reports results for the quarter ended December 2021.
How much does Moderna cost?
Moderna’s vaccine will also be more expensive than rivals, as it is likely to cost between $25 and $37 per dose, depending on the volume of the order, compared to about $19 per dose for the Pzifer vaccine. See our indicative theme of Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies.
How does Moderna work?
Once the genetic code of a virus is available, Moderna essentially adapts messenger RNA to trigger the immune system to produce protective antibodies without using the actual part of the virus , unlike traditional vaccines. For perspective, the Covid-19 vaccine was apparently designed within a few days. [4] .
How many doses of Moderna are there?
FDA last week, with vaccinations likely to begin as soon as Monday. Initial shipments are likely to stand at about 6 million doses, with total shipments by the end of the month likely to rise to about 20 million. This is larger than the Pfizer (NYSE: PFE) vaccine, which has delivered 2.9 million doses to date and has more stringent shipping and storage requirements. While the financial impact of the vaccine is likely to be limited for Moderna this quarter – with consensus pointing to about $250 million in Revenue, the number should scale up considerably to over $1.3 billion in Q1 2021, with Moderna likely to post a quarterly profit.
How much is Moderna revenue in 2021?
While the financial impact of the vaccine is likely to be limited for Moderna this quarter – with consensus pointing to about $250 million in Revenue, the number should scale up considerably to over $1.3 billion in Q1 2021, with Moderna likely to post a quarterly profit.
How is mRNA produced?
Unlike traditional vaccines which use a virus protein that needs to be grown over the course of weeks, mRNA molecules – which instruct the body to produce virus proteins by itself – are less complex and are produced via a chemical process (rather than a biological process) making mass production much quicker.
Where is Moderna manufactured?
Moderna is working with multiple partners to produce its vaccine. Switzerland-based Lonza, one of the world’s largest pharmaceutical services companies, will produce the key mRNA active ingredient for the vaccine in New Hampshire and Switzerland.
When will Moderna go to phase 3?
Moderna’s Cytomegalovirus (CMV) vaccine, which is currently in phase 2 studies and could move to phase 3 in 2021, is likely to be the company’s first candidate for approval after its Covid-19 vaccine. See our indicative theme of Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies.
What happened
Shares of Moderna (NASDAQ: MRNA) fell 13.5% on Monday after health officials indicated that the omicron variant might lead to less severe forms of COVID-19 than feared.
So what
Omicron is a heavily mutated strain of the novel coronavirus. It appears to be more transmissible than the already worrisome delta variant. Moreover, scientists don't yet know if currently available vaccines will be effective against omicron.
Now what
It should be noted that Fauci made it clear that it's too early to know for sure if omicron won't cause severe illness, or if it will in fact do so less often than other variants. U.S.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
What happened
Shares of Moderna (NASDAQ: MRNA) were down by 5.3% as of 1:25 p.m. ET Wednesday. The company announced a long-term collaboration with Thermo Fisher Scientific to manufacture messenger RNA (mRNA) vaccines. However, that wasn't the reason why Moderna's stock price slid.
So what
Sanofi and GlaxoSmithKline reported that the efficacy for two doses of their vaccine was 57.9%. That's well below the initial reported efficacy of 94% for a two-dose regimen of Moderna's COVID-19 vaccine, now being marketed as Spikevax. So why did Moderna's share price fall?
Now what
Sanofi and GSK are already in talks with the Food and Drug Administration and other regulatory agencies about submitting data to support the authorization of their COVID-19 vaccine. If the new vaccine is approved, it could negatively impact Moderna's future supply deals.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
What happened
Shares of several leading COVID-19 vaccine makers were falling as of 11:38 a.m. ET on Monday. Pfizer (NYSE: PFE) stock was down 3.5%. Shares of BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA) were sinking 7.6% and 8.2%, respectively.
So what
Investors should always look forward. And the number of COVID-19 vaccine doses sold by Pfizer, BioNTech, and Moderna could very well decline significantly after 2022 (or perhaps 2023).
Now what
Cuba Gooding, Jr.'s character in the movie Jerry Maguire had a famous line that seems applicable for Pfizer, BioNTech, and Moderna: "Show me the money." The main thing for investors to watch with all three companies is the money -- in particular, supply deals for COVID-19 vaccines for beyond 2022.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
